NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
6/8 — Strong
EVOTAZ (atazanavir and cobicistat) by Bristol Myers Squibb is cytochrome p450 3a inhibitors [moa]. First approved in 2015.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVOTAZ is a fixed-dose combination of atazanavir (protease inhibitor) and cobicistat (CYP3A inhibitor) approved in 2015 for HIV treatment. It works by inhibiting cytochrome P450 3A enzymes, blocking viral protease and enhancing atazanavir bioavailability. The combination reduces pill burden and improves pharmacokinetics in HIV-positive patients.
$0.012BPart D
Peak6.2 years to LOEProduct is at peak lifecycle stage with stable but modest Part D spending ($12M in 2023), indicating a mature portfolio asset with constrained commercial team expansion.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
Started May 2022
42 enrolled
Healthy Participants
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
Started Feb 2020
34 enrolled
Healthy Participants
Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
Started Jul 2016
13 enrolled
HIV
Taste Properties of Atazanavir and Cobicistat
Started Dec 2014
6 enrolled
HIV in Adults
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
Started Apr 2013
64 enrolled
Human Immunodeficiency Virus Type 1 (HIV-1)
Worked on EVOTAZ at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.